Currently, an increasing number of patients with malignancies are taking immune checkpoint inhibitors**, including PD-1 (or PD-L1) inhibitors and CTLA-4 inhibitors. Immune checkpoint inhibitors** such as PD-1 (or PD-L1) may also enhance immune damage to organs, tissues, etc., by killing tumor cells by enhancing anti-tumor immunity, especially in patients with pre-existing autoimmune diseases.
So, can patients with tumors with autoimmune diseases still be treated with immune checkpoint inhibitors such as PD-1 (or PD-L1)**?
Yes, but there are requirements. Immune checkpoint inhibitors such as PD-1 (or PD-L1)** can be used in patients with autoimmune disease who are stable, mildly active, or do not require **, but with caution and monitoring; Immune checkpoint inhibitors such as PD-1 (or PD-L1) are not suitable for patients with autoimmune neurological disease, life-threatening autoimmune disease, immunosuppressive drugs that cannot be controlled, or who require high-dose corticosteroids to control the disease**.
Further consultation with a medical professional or outpatient clinic can be made for further information.